Free Trial

ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis

-0.04 (-0.29%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
42,086 shs
Average Volume
63,457 shs
Market Capitalization
$872.21 million
P/E Ratio
Dividend Yield
Price Target

ABIVAX Société Anonyme MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
146.8% Upside
$34.20 Price Target
Short Interest
0.12% of Float Sold Short
Dividend Strength
News Sentiment
0.83mentions of ABIVAX Société Anonyme in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.98) to ($2.90) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

422nd out of 917 stocks

Pharmaceutical Preparations Industry

185th out of 426 stocks

ABVX stock logo

About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABVX Stock Price History

ABVX Stock News Headlines

ABVX ABIVAX Société Anonyme
Abivax S.A. ADR
ABIVAX Société Anonyme (ABVX.PA)
Abivax SA ABVX
See More Headlines
Receive ABVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Previous Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Market Cap
$872.21 million
Not Optionable
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Marc M. P. de Garidel M.B.A. (Age 66)
    CEO & Interim Chair of Board
    Comp: $862.25k
  • Dr. Philippe Pouletty M.D. (Age 66)
    Ph.D., Founder & Director
  • Mr. Didier Blondel (Age 60)
    EVP, CFO & Board Secretary
  • Mr. Didier Scherrer Ph.D. (Age 54)
    Chief Scientific Officer
  • Mr. Patrick Malloy
    Senior Vice President of Investor Relations
  • Ms. Ida Hatoum (Age 49)
    Chief People Officer
  • Mr. Pierre Courteille M.B.A. (Age 55)
    Chief Business Officer
  • Mr. Jerome Denis Ph.D.
    Executive Vice President of Process Development & Manufacturing
  • Mr. Sheldon Sloan M.B.E. (Age 65)
    M.D., Chief Medical Officer
  • Mr. Michael Ferguson B.S. (Age 46)
    M.B.A., Chief Commercial Officer

ABVX Stock Analysis - Frequently Asked Questions

Should I buy or sell ABIVAX Société Anonyme stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIVAX Société Anonyme in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABVX shares.
View ABVX analyst ratings
or view top-rated stocks.

What is ABIVAX Société Anonyme's stock price target for 2024?

6 analysts have issued twelve-month price objectives for ABIVAX Société Anonyme's shares. Their ABVX share price targets range from $16.00 to $50.00. On average, they anticipate the company's stock price to reach $34.20 in the next year. This suggests a possible upside of 146.8% from the stock's current price.
View analysts price targets for ABVX
or view top-rated stocks among Wall Street analysts.

How have ABVX shares performed in 2024?

ABIVAX Société Anonyme's stock was trading at $10.70 on January 1st, 2024. Since then, ABVX stock has increased by 29.5% and is now trading at $13.86.
View the best growth stocks for 2024 here

When did ABIVAX Société Anonyme IPO?

ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

When did the company's lock-up period expire?

ABIVAX Société Anonyme's lock-up period expired on Wednesday, April 17th. ABIVAX Société Anonyme had issued 18,699,460 shares in its public offering on October 20th. The total size of the offering was $216,913,736 based on an initial share price of $11.60. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are ABIVAX Société Anonyme's major shareholders?

ABIVAX Société Anonyme's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Blackstone Inc. (3.37%), Janus Henderson Group PLC (1.35%), Rosalind Advisors Inc. (0.60%), Kennedy Capital Management LLC (0.19%), Capstone Investment Advisors LLC (0.10%) and Sandia Investment Management LP (0.02%).

How do I buy shares of ABIVAX Société Anonyme?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABVX) was last updated on 5/25/2024 by Staff

From Our Partners